EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Prognostic Impact of EASIX According to the Timing of Assessment in Newly Diagnosed Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

Diana Fortoeș, Ion Antohe iD, Vlad-Andrei Cianga, Cosmin-Daniel Minciună iD, Elena Nicorici, Elena Dolachi-Pelin, Mihaela Zlei, Mihaela Mentel iD, Loredana Dragoș iD, Iuliu Ivanov, Andrada Uhl, Ciprian Tomuleasa iD und 1 weitere

Medical Sciences · 2026

DOI: 10.3390/medsci14060659 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Medical Sciences, 2026. Verfasst von Diana Fortoeș und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, Regional Oncology Institute, 700483 Iasi, Romania. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Endothelium, Vascular, Health Status Indicators, Multiple Myeloma. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: The Endothelial Activation and Stress Index (EASIX) is an easily accessible biomarker reflecting endothelial stress and has demonstrated prognostic value in several hematologic settings. However, its role in newly diagnosed multiple myeloma (NDMM), particularly according to the timing of assessment, remains insufficiently characterized. We evaluated the prognostic value of EASIX measured at diagnosis and immediately before autologous stem cell transplantation (autoSCT) for overall survival (OS) and progression-free survival (PFS).

Methods

This retrospective single-center study included 99 transplant-eligible patients with NDMM who underwent autoSCT between 2017 and 2023. EASIX was calculated at diagnosis and pre-autoSCT and log2-transformed. Survival was assessed using Kaplan–Meier analysis and Cox proportional hazards regression. Optimal EASIX thresholds were explored using maximally selected log-rank statistics. Model discrimination was evaluated using Harrell’s concordance index and time-dependent area under the curve (AUC).

Results

EASIX at diagnosis was available for 92 patients. Higher log2(EASIX) at diagnosis remained associated with inferior OS after adjustment for International Staging System (ISS) stage (HR 1.38, 95% CI 1.11–1.71; p = 0.0035). It also remained associated with shorter PFS after adjustment for ISS stage, age, and sex (HR 1.41, 95% CI 1.14–1.74; p = 0.001). Diagnosis EASIX demonstrated good discrimination for OS, with a C-index of 0.78 and sustained time-dependent AUC values. Conversely, pre-autoSCT EASIX was not significantly associated with OS or PFS when analyzed continuously, and cutoff-based analyses did not provide a consistent, robust prognostic signal.

Conclusions

EASIX measured at diagnosis was associated with both OS and PFS in transplant-eligible NDMM, whereas continuous pre-autoSCT EASIX showed no consistent association with either outcome. A direct paired comparison demonstrated a significantly stronger prognostic association of diagnosis EASIX with PFS, while the corresponding between-timepoint difference for OS was not statistically significant. These findings support further evaluation of EASIX timing in larger independent cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorEndothelium, VascularHealth Status IndicatorsMultiple MyelomaTime FactorsAdultAgedFemaleHumansMaleMiddle AgedCreatinineHematopoietic Stem Cell TransplantationL-Lactate DehydrogenasePlatelet CountPredictive Value of TestsPrognosisRetrospective StudiesRisk AssessmentTransplantation, Autologous

Stichwörter der Autor:innen

EASIXautologous stem cell transplantationendothelial dysfunctionmultiple myelomaoverall survivalprognostic biomarkerprogression-free survivalrisk stratification

Substanzen

Biomarkers, TumorCreatinineL-Lactate Dehydrogenase

Autor:innen und Institutionen

  • Hematology Department, Regional Oncology Institute, 700483 Iasi, Romania.
  • Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.
  • Flow Cytometry Department, Regional Oncology Institute, 700483 Iasi, Romania.
  • Molecular Diagnosis Department, Regional Institute of Oncology, 700483 Iasi, Romania.
  • Hematology Department, "Prof. Dr. Ion Chiricuta" Oncology Institute, 400015 Cluj-Napoca, Romania.
  • Hematology Department, Iuliu Hațieganu University of Medicine and Pharmacy, 400347 Cluj-Napoca, Romania.

ORCID-Profile: Ion Antohe, Cosmin-Daniel Minciună, Mihaela Mentel, Loredana Dragoș, Ciprian Tomuleasa, Angela Dăscălescu

Zitieren

APA

Fortoeș, D., Antohe, I., Cianga, V. A., Minciună, C. D., Nicorici, E., Dolachi-Pelin, E., Zlei, M., Mentel, M., Dragoș, L., Ivanov, I., Uhl, A., Tomuleasa, C., & Dăscălescu, A. (2026). Prognostic Impact of EASIX According to the Timing of Assessment in Newly Diagnosed Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Medical Sciences. https://doi.org/10.3390/medsci14060659

Vancouver

Fortoeș D, Antohe I, Cianga VA, Minciună CD, Nicorici E, Dolachi-Pelin E, et al. Prognostic Impact of EASIX According to the Timing of Assessment in Newly Diagnosed Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Medical Sciences. 2026. doi:10.3390/medsci14060659

BibTeX
@article{Fortoe2026,
  author = {Fortoeș, Diana and Antohe, Ion and Cianga, Vlad-Andrei and Minciună, Cosmin-Daniel and Nicorici, Elena and Dolachi-Pelin, Elena and Zlei, Mihaela and Mentel, Mihaela and Dragoș, Loredana and Ivanov, Iuliu and Uhl, Andrada and Tomuleasa, Ciprian and Dăscălescu, Angela},
  title = {Prognostic Impact of EASIX According to the Timing of Assessment in Newly Diagnosed Multiple Myeloma Undergoing Autologous Stem Cell Transplantation},
  journal = {Medical Sciences},
  year = {2026},
  doi = {10.3390/medsci14060659}
}
Kostenlos starten →